Johnson & Johnson said Monday that the Food and Drug Administration expanded the approval of its psoriasis drug Stelara, allowing the company to market Stelara as a treatment for psoriatic arthritis in adults.

Psoriatic arthritis is a form of arthritis that causes joint pain, stiffness and swelling in patients with psoriasis.

Stelara was approved in 2009 as a treatment for psoriasis. Revenue from the drug rose 50 percent to $371 million in the second quarter, including $233 million in U.S. sales. The expanded approval could increase sales.

Johnson & Johnson makes drugs, medical devices from bandages to surgical products, and over-the-counter medicines including Tylenol and Motrin. The company’s overall revenue grew 8.5 percent to $17.88 billion in the second quarter.

Shares of the New Brunswick, N.J., company slipped 67 cents to $89.01 in morning trading.